Background: To investigate whether the reason to discontinue the first TNF inhibitor (TNFi) affects the response to the second TNFi in axial spondyloarthritis (axSpA).
Methods: Patients with axSpA from the Rheumatic Diseases Portuguese Register (ReumaPt), who discontinued their first TNFi and started the second TNFi between June 2008 and May 2018, were included. Response was assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS) clinically important improvement (ASDAS-CII), major important improvement (ASDAS-MI), low disease activity (ASDAS-LDA), and inactive disease (ASDAS-ID). The reason for discontinuation of the first TNFi was defined, according to ASDAS-CII as primary failure (no response ≤ 6 months), secondary failure (response ≤ 6 months but lost thereafter), adverse events, and others. The association between the reason for discontinuation of the first TNFi and response to the second TNFi over time was assessed in multivariable generalized equation (GEE) models.
Results: In total, 193 patients were included. The reason for discontinuation of the first TNFi did not influence the response to the second TNFi, according to the ASDAS-CII. However, a difference was found with more stringent outcomes, e.g., there was a higher likelihood to achieve ASDAS-ID with the second TNFi for patients discontinuing the first TNFi due to secondary failure (OR 7.3 [95%CI 1.9; 27.7]), adverse events (OR 9.1 [2.5; 33.3]), or other reasons (OR 7.7 [1.6; 37.9]) compared to primary failure.
Conclusion: Patients with axSpA with secondary failure to their first TNFi, compared to those with primary failure, have a better response to the second TNFi according to stringent outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441644 | PMC |
| http://dx.doi.org/10.1186/s13075-020-02288-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis.
J Clin Med
November 2024
Division of Rheumatology, School of Medicine, Dokuz Eylul University, 35220 Izmir, Turkey.
CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (≥2nd-line) treatment in clinical practice.
View Article and Find Full Text PDFTNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry.
Reumatol Clin (Engl Ed)
December 2024
Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina. Electronic address:
Article Synopsis
- This study evaluated the effectiveness and persistence of golimumab (GLM) in patients with rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis who previously used other TNF inhibitors compared to those who haven't.
- A total of 192 patients were included, with follow-up results indicating that the majority discontinued GLM due to inefficacy, and the median survival for GLM treatment was similar for both experienced and naive patients.
- The study concluded that prior TNFi experience did not significantly affect the survival or persistence of GLM treatment, but having public health insurance was linked to higher discontinuation rates.
The Retention Rate and Safety of Secukinumab as a First-Line Biologic Agent in Axial Spondyloarthritis Compared to a First Tumor Necrosis Factor (TNF) Inhibitor: A Real-World, Longitudinal Study.
Cureus
September 2024
Department of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, MAR.
Background and objective Secukinumab (SECU) is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated effectiveness against axial spondyloarthritis (ax-SpA). However, in clinical practice, secukinumab is most commonly used as a second-line treatment after failure of or intolerance to tumor necrosis factor inhibitors (TNFi). In this study, we aimed to compare the two-year drug retention between secukinumab and TNFi in biologic-naïve patients with ax-SpA, to estimate the remission/low disease activity (LDA) rates in both groups and assess the safety profiles.
View Article and Find Full Text PDFInfections in psoriatic arthritis: association with treatment.
Ther Adv Musculoskelet Dis
October 2024
Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, Second Department of Medicine and Laboratory, National and Kapodistrian University of Athens School of Medicine, General Hospital of Athens Hippokration, 114 Vass. Sophias Avenue, Athens 115 27, Greece.
Article Synopsis
- - Serious infections (SIs) are a major concern for patients with psoriatic arthritis (PsA), especially when treated with various medications, including traditional options like methotrexate and newer biologics such as IL-23 inhibitors and JAK inhibitors.
- - While the overall incidence of SIs in PsA patients is lower than that in rheumatoid arthritis patients, there are ongoing safety concerns, particularly with the potential reactivation of latent infections like tuberculosis when using TNF inhibitors, which can be managed with proper screening.
- - Newer treatments like IL-23 inhibitors show no increase in common infection risk, but JAK inhibitors are associated with an elevated risk of herpes zoster, highlighting the importance of monitoring and preventive measures in treatment
Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis.
Clin Exp Rheumatol
October 2024
T-RAIG, TIMC, UMR 5525 CNRS, Univ. Grenoble Alpes, CHU Grenoble Alpes, Grenoble, and Department of Rheumatology, CHU Grenoble Alpes, Grenoble, France.
Article Synopsis
- The study evaluates the cost-effectiveness of tofacitinib as a second-line treatment after methotrexate failure for rheumatoid arthritis in France using a Markov model with 10,000 simulated patients.
- Introducing tofacitinib demonstrates cost savings of €1,679 per patient and increases quality-adjusted life years (QALYs) by 0.29 compared to traditional biologic treatments.
- This research is the first of its kind in France and agrees with findings from other countries, though it acknowledges limitations related to clinical trial data and focuses only on severe adverse effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!